Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach

Author:

Shekar NivruthiORCID,Vuong PatonORCID,Kaur ParwinderORCID

Abstract

Abstract Purpose This research focused on the identification of herbal compounds as potential anti-cancer drugs, especially for breast cancer, that involved the recognition of Notch downstream targets NOTCH proteins (1–4) specifically expressed in breast tumours as biomarkers for prognosis, along with P53 tumour antigens, that were used as comparisons to check the sensitivity of the herbal bio-compounds. Methods After investigating phytochemical candidates, we employed an approach for computer-aided drug design and analysis to find strong breast cancer inhibitors. The present study utilized in silico analyses and protein docking techniques to characterize and rank selected bio-compounds for their efficiency in oncogenic inhibition for use in precise carcinomic cell growth control. Results Several of the identified phytocompounds found in herbs followed Lipinski’s Rule of Five and could be further investigated as potential medicinal molecules. Based on the Vina score obtained after the docking process, the active compound Epigallocatechin gallate in green tea with NOTCH (1–4) and P53 proteins showed promising results for future drug repurposing. The stiffness and binding stability of green tea pharmacological complexes were further elucidated by the molecular dynamic simulations carried out for the highest scoring phytochemical ligand complex. Conclusion The target-ligand complex of green tea active compound Epigallocatechin gallate with NOTCH (1–4) had the potential to become potent anti-breast cancer therapeutic candidates following further research involving wet-lab experiments.

Funder

University of Western Australia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Reference144 articles.

1. Burstein HJ et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32(10):1216–1235. https://doi.org/10.1016/j.annonc.2021.06.023

2. ‘Breast cancer’. https://www.who.int/news-room/fact-sheets/detail/breast-cancer . Accessed 25 May 2023

3. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA: Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

4. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA: Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654

5. ‘Breast cancer|Elsevier Enhanced Reader’. https://reader.elsevier.com/reader/sd/pii/S0140673620323813?token=F04EE001F4AFA148D57A6A18E312759B1B7668E8D437C2F0884D470AD396C5CE814A78A340AB299BD62E2935A33FB6C4&originRegion=us-east-1&originCreation=20230323035152. Accessed 23 Mar 2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3